Relay Therapeutics, Inc. (RLAY) — Financial statements
Income statement, balance sheet, and cash flow for Relay Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 15↑53.4% | 10↓60.8% | 26↑1749.8% | 1↓54.4% | 3 | |
| Cost of Revenue | 4 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 12↑17.9% | 10↓60.8% | 26↑1749.8% | 1↓54.4% | 3 | |
| Operating Expenses | ||||||
| R&D Expenses | 261↓18.1% | 319↓3.3% | 330↑34.0% | 246↑42.7% | 173 | |
| General & Administrative Expenses | 57↓26.0% | 77↑2.2% | 75↑13.6% | 66↑15.0% | 57 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 57↓26.0% | 77↑2.2% | 75↑13.6% | 66↑15.0% | 57 | |
| Other Expenses | -4↑73.1% | -13↓105.6% | -6↑45.0% | -12↓108.5% | 138 | |
| Operating Expenses | 315↓17.8% | 382↓4.0% | 399↑32.6% | 301↓18.2% | 368 | |
| Total Costs & Expenses | 318↓16.8% | 382↓4.0% | 399↑32.6% | 301↓18.2% | 368 | |
| Operating Results | ||||||
| Operating Income | -303↑18.7% | -372↑0.1% | -373↓24.6% | -299↑17.9% | -365 | |
| Depreciation & Amortization | 4↓34.9% | 5↑3.7% | 5↑27.6% | 4↑5.2% | 4 | |
| EBITDA | -273↑28.2% | -380↓1.6% | -374↓21.9% | -307↓37.5% | -223 | |
| EBIT | -276↑28.3% | -386↓1.6% | -379↓22.0% | -311↓37.0% | -227 | |
| Interest & Other Income | ||||||
| Net Interest Income | 27↓22.2% | 35↑11.9% | 31↑253.3% | 9↑958.6% | 0.83 | |
| Interest Income | 27↓22.2% | 35↑11.9% | 31↑253.3% | 9↑958.6% | 0.83 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -26↓298.8% | 13↑105.6% | 6↓45.0% | 12↑108.5% | -138 | |
| Other Income / Expenses | 26↓24.5% | 35↑12.0% | 31↑253.9% | 9↑961.3% | 0.83 | |
| Income Before Tax | -276↑18.1% | -338↑1.2% | -342↓17.7% | -291↑20.2% | -364 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -276↑18.1% | -338↑1.2% | -342↓17.7% | -291↑20.2% | -364 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -276↑18.1% | -338↑1.2% | -342↓17.7% | -291↑20.2% | -364 | |
| Bottom-Line Net Income | -276↑18.1% | -338↑1.2% | -342↓17.7% | -291↑20.2% | -364 | |
| EPS (Basic) | -1.61↑31.8% | -2.36↑15.4% | -2.79↓7.7% | -2.59↑32.2% | -3.82 | |
| EPS (Diluted) | -1.61↑31.8% | -2.36↑15.4% | -2.79↓7.7% | -2.59↑32.2% | -3.82 | |
| Weighted Average Shares | 172↑20.1% | 143↑16.6% | 123↑9.2% | 112↑18.0% | 95 | |
| Weighted Average Diluted Shares | 172↑20.1% | 143↑16.6% | 123↑9.2% | 112↑18.0% | 95 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.